Search

Summary: Management of classical Hodgkin lymphoma in older patients is challenging due to poor tolerance of the chemotherapy regimens used in younger patients. We modified the BEACOPP regimen (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisolone), whereby bleomycin and etoposide were removed and cyclophosphamide dose was reduced, for older patients with co‐morbidities. Here we present data from the first 41 patients treated with 'ACOPP' across 3 centres, demonstrating that it can be delivered, with a favourable toxicity profile (TRM 2%) and promising efficacy (2‐year PFS and OS, 73% (95% CI: 52–94) and 93% (95% CI: 80–100) respectively). [ABSTRACT FROM AUTHOR]

The article discusses a guideline compiled by the British Society for Haematology (BSH) for the management of mantle cell lymphoma (MCL). Topics covered include first line management for early stage and advanced stage MCL as well as indications for treatment, how to determine patients fit for autologous stem cell transplant, and therapeutic algorithm for alternative immunochemotherapy, Bruton tyrosine kinase (BTK) inhibitor or other targeted therapy.

Clinically and biologically, nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) has much more in common with germinal-center derived B-cell non-Hodgkin lymphoma (NHL) than with classical Hodgkin lymphoma (cHL). Management of NLPHL remains controversial. In a 14-year multicenter series, 69 cases were analyzed, and the median follow-up was 53 months (range 11-165.) B-symptoms were present in only 4.3%% of patients, and 81.1%% of patients had stage I/II disease. Treatment was with radiotherapy (53.6%%), chemotherapy (21.7%%), combined modality (17.4%%), and observation (7.2%%). In all, 10.1%% of patients relapsed and 2.9%% of patients developed high-grade transformation to DLBCL. All relapses and transformations were salvageable. No patient died of their disease. The 5-year relapse-free survival was 92%%, transformation-free survival 98.4%%, and overall survival 100%%. We conclude that NLPHL behaves as a distinct clinical entity, often presenting at an early stage without risk factors. It has an excellent outcome. It may be possible, in early-stage disease, to reduce the intensity of therapy in NLPHL, to single-modality radiotherapy, without affecting OS. [ABSTRACT FROM AUTHOR]